Vol. 63 No. 6 (2017), ORIGINAL ARTICLES. A. PROTOCOLS OF CLINICAL RESEARCH

Vol. 63 No. 6 (2017)

INFLUENCE OF CLINICAL CHARACTERISTICS AND VOLUME OF CYTOREDUCTION IN PATIENTS WITH PRIMARY GLIOBLASTOMA ON OVERALL SURVIVAL

ORIGINAL ARTICLES. A. PROTOCOLS OF CLINICAL RESEARCH

https://doi.org/10.37469/0507-3758-2017-63-6-907-914

Published 01.06.2017

Marina Matsko⁺⁻
Dmitriy Matsko⁺⁻
Nikita Volkov⁺⁻
Aleksey Ulitin⁺⁻
Aglaya Ievleva⁺⁻

Marina Matsko

A.L. Polenov Russian Neurosurgical Institute, V.A. Almazov Federal Medical Research Center, St. Petersburg Clinical Scientific and Practical Center of Specialized Medical Assistance (Oncological), St. Petersburg State University, St. Petersburg Medico-Social Institute

Dmitriy Matsko

Nikita Volkov

St. Petersburg Clinical Scientific and Practical Center of Specialized Medical Assistance (Oncological), St. Petersburg Medico-Social Institute

Aleksey Ulitin

A.L. Polenov Russian Neurosurgical Institute, V.A. Almazov Federal Medical Research Center, I.I. Mechnikov North-West State Medical University

Aglaya Ievleva

N.N. Petrov National Medical Research Center of Oncology, St. Petersburg State Pediatric Medical University

##article.numberofdownloads## 37

##article.numberofviews## 159

PDF (Русский)

Keywords

GLIOBLASTOMA
SURVIVAL
PROGNOSTIC FACTORS

How to Cite

Matsko, M., Matsko, D., Volkov, N., Ulitin, A., & Ievleva, A. (2017). INFLUENCE OF CLINICAL CHARACTERISTICS AND VOLUME OF CYTOREDUCTION IN PATIENTS WITH PRIMARY GLIOBLASTOMA ON OVERALL SURVIVAL. Voprosy Onkologii, 63(6), 907–914. https://doi.org/10.37469/0507-3758-2017-63-6-907-914

Abstract

Patients with glioblastoma (GB) rarely survive more than 3 years. This study aimed to analyze clinical characteristics of long-term GB survivors. 69 patients with primary GB who were treated at the A.L. Polenov Neurosurgical Institute since 2009 and had sufficient follow-up were analyzed; survival of 11 of these patients exceeded 3 years, while the remaining 58 failed to achieve this threshold. An immunohistochemical study was performed using Ki-67 and GFAP antibodies. Patients were divided into two groups: the first included 11 patients with a survival rate of more than 3 years, the second (comparison group) with a survival rate of less than 3 years included 58 patients. Long-term survival correlated with the younger patients age (p = 0.002) and tumor response to temozolomide (p = 0.004). Other clinical features, including gender (p = 0.484), Karnovsky status (p = 0.322); tumor location (p = 0.078), volume of the lesion and the number of affected lobes (p = 0.132), the number of surgical interventions (p = 0.278) and the volume of cytoreduction (p = 0.105) were not prognostic in this small patient cohort.

https://doi.org/10.37469/0507-3758-2017-63-6-907-914

##article.numberofdownloads## 37

##article.numberofviews## 159

PDF (Русский)

References

Горяйнов С.А., Гольдберг М.Ф., Голанов А.В. и др. Феномен длительной выживаемости пациентов с глиобласто-мами. Часть I: роль клинико-демографических факторов и мутации IDH1 (R132H) // Журнал вопросы нейрохирургии им. Н.Н. Бурденко. - 2017. - № 3. - С. 5-16.

Adeberg S., Bostel Т., König L. et all. A comparison of long-term survivors and short-term survivors with glioblastoma, subventricular zone involvement: a predictive factor for survival? // Radiat Oncol. - 2014. - Vol. 9(1).

Amelot A., De Cremoux P., Quillien V. et all. IDH-Mutation is a weak predictor of long-term survival in glioblastoma patients // PLoS One. - 2015. - Vol. 10(7). - e0130596.

Barbagallo G.M., Paratore S., Caltabiano R. et all. Longterm therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles // Neurosurg Focus. - 2014. - Vol. 37(6). - P. E4.

Bloch O., Han S.J., Cha S. et all. Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article // J. Neurosurg. - 2012. - Vol. 117(6). - P 1032-1038.

Burton E.C., Lamborn K.R., Forsyth P. et all. Aberrant p53, mdm2, and proliferation differ in glioblastomas from long-term compared with typical survivors // Clin. Cancer Res. - 2002. - Vol. 8(1). - P 180-187.

Chaichana K.L., Garzon-Muvdi Т., Parker S. et all. Supra-tentorial glioblastoma multiforme: the role of surgical resection versus biopsy among older patients // Ann Surg. Oncol. - 2011. - Vol. 18(1). - P 239-245.

Chaichana K.L., Pendleton C., Chambless L. et all. Multi-institutional validation of a preoperative scoring system which predicts survival for patients with glioblastoma // J. Clin. Neurosci. - 2013. - Vol. 20(10). - P. 1422-1426.

Feng Y, Wang Z., Bao Z. et all. SOCS3 promoter hyper-methylation is a favorable prognosticator and a novel indicator for G-CIMP-positive GBM patients // PLoS One. - 2014. - Vol. 9(3). - e91829.

Field K.M., Rosenthal M.A., Yilmaz M. et all. Comparison between poor and long-term survivors with glioblastoma: review of an Australian dataset // Asia Pac. J. Clin. Oncol. - 2014. - Vol. 10(2). - P 153-161.

Fiore D., Donnarumma E., Roscigno G. et all. miR-340 predicts glioblastoma survival and modulates key cancer hallmarks through down-regulation of NRAS // Oncotarget. - 2016. - Vol. 7(15). - P. 19531-19547.

Geisenberger C., Mock A., Warta R. et all. Molecular profiling of long-term survivors identifies a subgroup of glioblastoma characterized by chromosome 19/20 co-gain // Acta Neuropathol. - 2015. - Vol. 130(3). - P 419-434.

Gerber N.K., Goenka A., Turcan S. et all. Transcriptional diversity of long-term glioblastoma survivors // Neuro Oncol. - 2014. - Vol. 16(9). - P 1186-1195.

Gilbert M.R., Dignam J.J., Armstrong T.S. et all. A randomized trial of bevacizumab for newly diagnosed glioblastoma // N. Engl. J. Med. - 2014. - Vol. 370(8). - P. 699-708.

Glas M., Happold C., Rieger J. et all. Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide // J. Clin. Oncol. - 2009. - Vol. 27(8). - P 1257-1261.

Johnson D.R., Leeper H.E., Uhm J.H. Glioblastoma survival in the United States improved after Food and Drug Administration approval of bevacizumab: a population-based analysis // 2013. - Vol. 119(19). - P. 3489-3495.

Johnson D.R., Ma D.J., Buckner J.C., Hammack J.E. Conditional probability of long-term survival in glioblastoma: a population-based analysis // Cancer. - 2012. - Vol. 118(22). - P. 5608-5613.

Korshunov A., Sycheva R., Golanov A. Genetically distinct and clinically relevant subtypes of glioblastoma defined by array-based comparative genomic hybridization (array-CGH) // Acta Neuropathol. - 2006. - Vol. 111(5). - P. 465-474.

Lacroix M., Abi-Said D., Fourney D.R. et all. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival // J. Neurosurg. - 2001. - Vol. 95(2). - P. 190-198.

Martinez R., Schackert G., Esteller M. Hypermethylation of the proapoptotic gene TMS1/ASC: prognostic importance inglioblastoma multiforme // J. Neurooncol. - 2007. - Vol. 82(2). - P. 133-139.

Martinez R., Schackert G., Yaya-Tur R. et all. Frequent hypermethylation of the DNA repair gene MGMT in longterm survivors of glioblastoma multiforme // J. Neurooncol. - 2007. - Vol. 83(1). - P. 91-93.

Mazaris P., Hong X., Altshuler D. et all. Key determinants of short-term and long-term glioblastoma survival: a 14-year retrospective study of patients from the Hermelin Brain Tumor Center at Henry Ford Hospital // Clin. Neurol. Neurosurg. - 2014. - Vol. 120. - P. 103-112.

McGirt M.J., Chaichana K.L., Gathinji M. et all. Independent association of extent of resection with survival in patients with malignant brain astrocytoma // J. Neurosurg. - 2009. - Vol. 110(1). - P. 156-162.

Millward C.P., Brodbelt A.R., Haylock B. et all. The impact of MGMT methylation and IDH-1 mutation on long-term outcome for glioblastoma treated with chemoradiotherapy // Acta Neurochir (Wien). - 2016. - Vol. 158(10). - P. 1943-1953.

Netsky M.G., August B., Fowler W. The longevity of patients with glioblastoma multiforme // J. Neurosurg. - 1950. - Vol. 7(3). - P. 261-269.

Nomiya T, Nemoto K., Kumabe T. et all. Prognostic significance of surgery and radiation therapy in cases of anaplastic astrocytoma: retrospective analysis of 170 cases // J. Neurosurg. - 2007. - Vol. 106(4). - P. 575-581.

Oszvald A., G resir E., Setzer M. et all. Glioblastoma therapy in the elderly and the importance of the extent of resection regardless of age // J. Neurosurg. - 2012. - Vol. 116(2). - P. 357-364.

Reifenberger G., Weber R.G., Riehmer V. et all. Molecular characterization of long-term survivors of glioblastoma using genome- and transcriptome-wide profiling // Int. J. Cancer. - 2014. - Vol. 135(8). - P. 1822-1831.

Rulseh A.M., Keller J., Klener J. et all. Long-term survival of patients suffering from glioblastoma multiforme treated with tumor-treating fields // World J. Surg. Oncol. - 2012. - Vol. 10(220).

Sanai N., Polley M.Y., McDermott M.W. et all. An extent of resection threshold for newly diagnosed glioblastomas // J. Neurosurg. - 2011. - Vol. 115(1). - P. 3-8.

Schneider J.P., Trantakis C., Rubach M. et all. Intraoperative MRI to guide the resection of primary supratentorial glioblastoma multiforme - a quantitative radiological analysis // Neuroradiology. - 2005. - Vol. 47(7). - P. 489-500.

Scoccianti S., Magrini S.M., Ricardi U. et all. Patterns of care and survival in a retrospective analysis of 1059 patients with glioblastoma multiforme treated between 2002 and 2007: a multicenter study by the Central Nervous System Study Group of Airo (Italian Association of Radiation Oncology) // Neurosurgery. - 2010. - Vol. 67(2). - P. 446-458.

Scott J.N., Rewcastle N.B., Brasher P.M. et all. Which glioblastoma multiforme patient will become a long-term survivor? A population-based study // Ann. Neurol. - 1999. - Vol. 46(2). - P. 183-188.

Shannon S., Vaca C., Jia D. et all. Dexamethasone-me-diated activation of fibronectin matrix assembly reduces dispersal of primary human glioblastoma cells // PLoS One. - 2015. - Vol. 10(8). - e0135951.

Stummer W., Pichlmeier U., Meinel T. et all. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial // Lancet Oncol. - 2006. - Vol. 7(5). - P. 392-401.

Vertosick F.T., Selker R.G. Long-term survival after the diagnosis of malignant glioma: a series of 22 patients surviving more than 4 years after diagnosis // Surg. Neurol. - 1992. - Vol. 38(5). - P. 359-363.

Weller M., Felsberg J., Hartmann C. et all. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network // J. Clin. Oncol. - 2009. - Vol. 27(34). - P. 5743-5750.

Wen P.Y., Macdonald D.R., Reardon D.A. et all. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group // J. Clin. Oncol. - 2010. - Vol. 28(11). - P. 1963-1972.

Zhang G.B., Cui X.L., Sui D.L. et all. Differential molecular genetic analysis in glioblastoma multiforme of long- and short-term survivors: a clinical study in Chinese patients // J. Neurooncol. - 2013. - Vol. 113(2). - P. 251-258.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Most read articles by the same author(s)

Marina Popova, Andrey Chekalov, Ivan Tsygankov, Yuliya Rogacheva, Marina Demchenkova, Maria Grigoreva, Olga Uspenskaya, Olga Ruzhinskaya, Vsevolod Potapenko, Nadezhda Medvedeva, Ilya Zyuzgin, Kamil Kaplanov, Tatiana Ksenzova, Alexander Levanov, Olga Samoylova, Nikita Volkov, Anastasya Beynarovich, Artem Gusak, Kirill Lepik, Nataliya Mikhailova, Vadim Baykov, Alexander Kulagin, Burkitt lymphoma in patients with HIV infection: results of a Russian multicenter study , Voprosy onkologii : Vol. 68 No. 6 (2022)
Anastasya Nechaeva, Marina Matsko, Aleksandr Ulitin, Andrey Zrelov, Primary central nervous system neuroblastomas and ganglioneuroblastomas in adult patients , Voprosy onkologii : Vol. 69 No. 2 (2023)
Svetlana Aleksakhina, Aglaya Ievleva, Anna Sokolenko, Sofia Baskina, Ajgul Venina, Elena Anisimova, Nurmagomed Akhmedov, Alexandr Ivantsov, Yana Belysheva, Alexandra Chernyakova, Evgeny Imyanitov, Loss of heterozygosity in CHEK2-associated breast cancer , Voprosy onkologii : Vol. 67 No. 5 (2021)
Aleksandr S Martianov, Fedor Moiseenko, Albina Zhabina, Tatyana Sokolova, Sergey Beluhin, Tatiana Laidus, Maxim Kholmatov, Vladislav Turin, Nikita Volkov, Ekaterina Kuligina, Grigoiy Yanus, Changes in the concentration of EGFR-mutated plasma DNA in the first hours of anti-EGFR therapy allow the prediction of tumor response in patients with EGFR-driven lung cancer , Voprosy onkologii : Vol. 67 No. 5 (2021)
Lev Bershteyn, Tatyana Poroshina, Zamira Radzhabova, Irina Kovalenko, Aleksandr Ivantsov, Aglaya Ievleva, Igor Berlev, COMPARATIVE FEATURES OF CARBOHYDRATE METABOLISM STATE, BODY WEIGHT AND ASSOCIATED HORMONAL FACTORS IN VARIOUS MOLECULAR-BIOLOGICAL TYPES OF ENDOMETRIAL CANCER , Voprosy onkologii : Vol. 64 No. 3 (2018)
Lev Bershteyn, Aglaya Ievleva, Aleksandr Ivantsov, D. Vasiliev, Maksim Kleshchev, Tatyana Poroshina, Irina Kovalenko, A. Venina, I. Berlev, MODERN MOLECULAR BIOLOGICAL TYPES OF ENDOMETRIAL CANCER: COMPARATIVE ENDOCRINE AND PROINFLAMMATORY-PROGENOTOXIC CHARACTERISTICS , Voprosy onkologii : Vol. 65 No. 2 (2019)
Fedor Moiseenko, Vladislav Tyurin, Nikita Levchenko, Yevgeniy Levchenko, Aglaya Ievleva, Yevgeniy Imyanitov, Natalya Mityushkina, DETECTION OF RESIDUAL LUNG CANCER CELLS BY PCR-BASED GENETIC TESTING FOR ROS1-TRANSLOCATION: CASE REPORT , Voprosy onkologii : Vol. 64 No. 3 (2018)
Fedor Moiseenko, Mariya Stepanova, Nikita Volkov, Albina Zhabina, A. Myslik, Anna Meldo, N. Rysev, D. Krylova, V. Klimenko, Andrey Bogdanov, Vladimir Moiseenko, PREDICTIVE VALUE OF THE DYNAMIC DETERMINATION OF CIRCULATING TUMOR DNA ON PFS IN PATIENTS WITH EGFR MUTATED NSCLC, WITH OSIMERTINIB THERAPY , Voprosy onkologii : Vol. 66 No. 2 (2020)
Georgiy Gafton, Valentin Anisimov, Dmitriy Matsko, Aleksandr Ivantsov, Ivan Gafton, M. Myasnyankin, LONG-TERM RESULTS OF TREATMENT OF PATIENTS WITH SUBUNGUAL MELANOMA , Voprosy onkologii : Vol. 63 No. 3 (2017)
Lev Bershteyn, Aleksandr Ivantsov, Aglaya Ievleva, A. Venina, I. Berlev, STEROID RECEPTOR PHENOTYPE, EXPRESSION OF HER-2/NEU, PD-1, PD-L1 AND LYMPHOCYTIC-MACROPHAGAL INFILTRATION OF ENDOMETRIAL CARCINOMAS: COMPARISON OF MODERN MOLECULAR BIOLOGICAL TYPES OF THE DISEASE (THE ROLE OF BODY MASS INDEX) , Voprosy onkologii : Vol. 66 No. 1 (2020)

1 2 > >>